Source comparison
PT-141 Differs from Vyleesi — Comparison
Active Compound Bremelanotide (cyclic heptapeptide) Molecularly identical. Same amino acid sequence and receptor targets Regulatory Status Research use only, not FDA-approved as a drug FDA-approved (2019) for acquired, generalized HSDD in premenopausal women V
This comparison does not assign a generated winner or score.
- Active Compound
- Bremelanotide (cyclic heptapeptide)
- Molecularly identical. Same amino acid sequence and receptor targets
- Regulatory Status
- Research use only, not FDA-approved as a drug
- FDA-approved (2019) for acquired, generalized HSDD in premenopausal women
- Vyleesi undergoes full regulatory oversight; PT-141 does not
- Formulation
- Lyophilized powder requiring reconstitution
- Pre-filled autoinjector, 1.75 mg in sterile solution
- Vyleesi formulation eliminates user error in reconstitution and dosing
- Quality Oversight
- Varies by supplier; CoA verification recommended
- cGMP manufacturing with batch-level potency and sterility testing
- PT-141 quality is supplier-dependent; Vyleesi quality is FDA-mandated
- Legal Access
- Available for research purposes from peptide suppliers
- Prescription-only medication dispensed through licensed pharmacies
- Vyleesi requires prescriber authorization; PT-141 does not in research contexts
- Typical Dosing
- Variable (investigational protocols range 0.75–20 mg)
- 1.75 mg subcutaneously, max 1 dose per 24 hours, max 8 doses per month
- Vyleesi dose is evidence-based from Phase 3 trials; PT-141 dosing is protocol-specific
- Cost
- $50–$150 per vial (varies by supplier and purity)
- $800–$1,000 per dose without insurance
- PT-141 is significantly less expensive but lacks regulatory drug approval
- The comparison clarifies that PT-141 differs from Vyleesi in the manufacturing pathway, regulatory approval, and quality assurance infrastructure. Not in the active molecule itself. For clinical therapeutic use in humans, only Vyleesi is legally accessible through prescription. For research applications in controlled laboratory settings, PT-141 sourced from reputable peptide synthesis facilities offers the same compound at lower cost with the understanding that quality verification is the researcher's responsibility.